A phase II trial of bevacizumab plus erlotinib for patients with metastatic gemcitabine-refractory pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2009 Planned end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.